Last reviewed 2026-05-14 · How we verify

DTaP-HB-PRP~T vaccine

DTaP-HB-PRP~T vaccine is a Combination vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Primary immunization against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b in infants and children.

This combination vaccine stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b (Hib) pathogens.

This combination vaccine stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b (Hib) pathogens. Used for Primary immunization against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b in infants and children.

At a glance

Mechanism of action

DTaP-HB-PRP~T is a pentavalent vaccine containing inactivated toxoids (diphtheria and tetanus), acellular pertussis antigens, hepatitis B surface antigen, and Hib polysaccharide conjugate. It works by presenting these antigens to the immune system to generate humoral and cellular immune responses, resulting in protective antibodies and immunological memory against these five serious bacterial diseases.

Approved indications

• Primary immunization against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b in infants and children

Common side effects

• Injection site reactions (pain, redness, swelling)
• Fever
• Irritability
• Drowsiness

Key clinical trials

• Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
• Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
• Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea
• Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
• Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
• Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico (PHASE3)
• DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants (PHASE3)
• Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• DTaP-HB-PRP~T vaccine CI brief — competitive landscape report
• DTaP-HB-PRP~T vaccine updates RSS · CI watch RSS
• Sanofi Pasteur, a Sanofi Company portfolio CI

Frequently asked questions about DTaP-HB-PRP~T vaccine

Related

• Drug class: All Combination vaccine drugs
• Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
• Therapeutic area: All drugs in Immunology
• Indication: Drugs for Primary immunization against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b in infants and children
• Compare: DTaP-HB-PRP~T vaccine vs similar drugs
• Pricing: DTaP-HB-PRP~T vaccine cost, discount & access